Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Advisory Committee On Dextromethorphan Raises Stakes On Age Restriction

Executive Summary

The Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare

You may also be interested in...

Senate Meth Fight Pits Rx-Only Pseudoephedrine Against E-Tracking Option

The debate over how best to keep methamphetamine precursors from diversion to illicit drug labs is coming to a head as lawmakers stake out positions and legislation to restrict nonprescription access to pseudoephedrine waits in the wings

Annual survey shows OTC product abuse flat in 2009

Results from the National Institute on Drug Abuse's Monitoring the Future survey for 2009 show little change since 2006 in the rate teens are abusing OTC cough/cold products, such as dextromethorphan-containing cough medicine. The Consumer Healthcare Products Association notes while there has not been an increase, the findings serve "as a reminder of the importance of education and talking to teens about the dangers" of OTC drug abuse. The survey is conducted by the University of Michigan (1"The Tan Sheet" Dec. 22, 2008, In Brief)

“Snurf” Abuse Reports Revive Interest In DXM Bills

A recent report of young people suspected of abusing "Snurf" has reignited interest on Capitol Hill in restricting bulk purchases of raw dextromethorphan and an age restriction on OTCs containing the cough suppressant


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts